Bayer Pharma AG

About coronary and peripheral artery disease

About coronary and peripheral artery disease

Coronary artery disease (CAD) and peripheral arterial disease (PAD) often coexist, and the latter is a marker of systemic atherosclerosis. Most patients with PAD also have concomitant CAD, and a large burden of morbidity and mortality in patients with PAD is related to myocardial infarction, ischaemic stroke and cardiovascular death. A better understanding of the underlying pathophysiological association between CAD and PAD will lead to the development of safer and more effective therapeutic options that could benefit the clinical management of patients with one or both of these diseases.


Steering Committee Films Pregnancy

Steering Committee Films Pregnancy

Sylvia Haas discusses the increased risk of thrombosis during pregnancy and the unique challenges of treating this special patient population. Find out more by visiting the Thrombosis and Pregnancy section of the website.

Sylvia Haas discusses the increased risk of thrombosis during pregnancy and the unique challenges of treating this special patient population. Find out more by visiting the Thrombosis and Pregnancy section of the website.


Coronary and peripheral artery disease as risk factors for arterial thrombosis

A link between atherothrombosis and ischaemia is now well recognized. A better understanding of the underlying pathophysiological mechanisms will give new insights into the development of more-effective and safer anticoagulants for secondary prevention of acute atherothrombosis, with a therapeutic benefit for patients with coronary and/or peripheral artery disease.


Lungs Pulmonary Embolism

The pathway of a pulmonary embolism (PE) from the lower half of the body: inferior vena cava, to right atrium, to right ventricle, to the pulmonary artery. This might eventually obstructs blood flow to the lung. Patients with deep vein thrombosis (DVT) are at risk of PE, a life-threatening event.

The pathway of a pulmonary embolism (PE) from the lower half of the body: inferior vena cava, to right atrium, to right ventricle, to the pulmonary artery. This might eventually obstructs blood flow to the lung. Patients with deep vein thrombosis (DVT) are at risk of PE, a life-threatening event.

Download


Management of coronary and peripheral artery disease

Coronary artery disease and peripheral artery disease management may be complex owing to common comorbidities, which may also require treatment (e.g. diabetes, hyperlipidaemia, obesity and hypertension). Management can be improved with increased physician and patient education and use of the latest guidelines.


Venous valves

Venous valves

Venous valves playing with an acute and non adherent thrombus in an enlarged posterior tibial vein in a sitting patient

Venous valves playing with an acute and non adherent thrombus in an enlarged posterior tibial vein in a sitting patient


Cancer increases the risk of venous thromboembolism

Patients with cancer face an increased risk of venous thromboembolism (VTE) as malignancy is associated with a hypercoagulable state and the use of chemotherapy agents may also contribute to an increased risk. In fact, VTE is a significant cause of morbidity and mortality in patients with cancer. Risk factors for cancer-associated VTE include: tumour type; age; stage of cancer; and VTE history. Risk stratification and use of biomarker-based approaches may assist in the provision of targeted thromboprophylaxis. The use of a validated predictive model for VTE risk in patients with cancer receiving chemotherapy may also enable clinicians to determine whether patients are at particularly high risk of VTE.